Teva Pharma's most recent trend suggests a bullish bias. One trading opportunity on Teva Pharma is a Bull Put Spread using a strike $40.00 short put and a strike $35.00 long put offers a potential 5.04% return on risk over the next 36 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $40.00 by expiration. The full premium credit of $0.24 would be kept by the premium seller. The risk of $4.76 would be incurred if the stock dropped below the $35.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Teva Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Teva Pharma is bullish.
The RSI indicator is at 78.52 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Teva Pharma
2014 Trend Alert: Health-Care M&A
Sat, 18 Jan 2014 22:49:59 GMT
Motley Fool – Are Bristol-Myers Squibb and Teva on the hunt for some M&A opportunities?
Israel ETFs Breakout
Fri, 17 Jan 2014 13:15:29 GMT
ETF Trends – To start 2014, some of last year’s top-performing developed markets are stumbling. Perhaps it is telling that the Global X FTSE Portugal 20 ETF (NYSEArca: PGAL) is the best developed markets ETF and the …
This biotech could help you retire early
Thu, 16 Jan 2014 20:45:38 GMT
Motley Fool – Mesoblast is a clear standout in the biotechnology sector.
[$$] Galena Biopharma Gets a Gateway to Asia
Thu, 16 Jan 2014 12:54:00 GMT
Barrons.com – Galena Biopharma (GALE: Nasdaq) By Roth Capital Partners ($7.24, Jan. 14, 2014) We reiterate our Buy rating on Galena Biopharma and are raising our price target to $12 from $11. We believe that Galena's …
Teva Shares Gain as CFO Signals Appetite for Acquisitions
Wed, 15 Jan 2014 15:41:01 GMT
Bloomberg – Teva Pharmaceutical Industries Ltd. rose to a one-year high after the maker of generic medicines said it plans to return to a deal-making strategy that made it one of the most acquisitive drug companies …
Also on Market Tamer…
Follow Us on Facebook